



Handouts for Patients and Families (available on the accompanying CD) are included in the index and are indicated by “CD” rather than page numbers.

- AAC. *See* Augmentative communication system (AAC)
- AAC-RERC. *See* Rehabilitation Engineering Research Center on AAC (AAC-RERC)
- Academy of Neurologic Communication Disorders and Sciences (ANCDS), CD
- Acetylcholine, 79
- Acid indigestion, CD
- Acquired Parkinson’s disease, 69
- ACTH (adrenocorticotrophic hormone), 152
- ADA (Americans With Disabilities Act), 154
- Adrenocorticotrophic hormone (ACTH), 152
- Advanced health care directive, 177
- Affective disorders. *See also* Depression
 - with ALS, 8, 12, 30, 222
 - with multiple sclerosis, 150
- AFO. *See* Ankle-foot orthosis (AFO)
- Akinesia, 71–73
- Alerting systems, 37
- Alimentation, 221
- Alphabet boards and alphabet supplementation, 37, 102, 131–132, 163, 221
- ALS. *See* Amyotrophic lateral sclerosis (ALS)
- ALS Association of America (ALSA), 7, CD
- ALS Functional Rating Scale–Revised*, 4
- ALS Health State Scale*, 4–5
- ALS Severity Scale, 24–29, 42, 43–44, 55–57
- Alternate motion rates, 177–179
- American Academy of Neurology, 6, 14, 17
- American Parkinson Disease Association (APDA), CD
- American Speech-Language-Hearing Association (ASHA), CD
- Americans With Disabilities Act (ADA), 154
- Amplifier, 221
- Amyotrophic lateral sclerosis (ALS)
 - age at onset of, x
 - alternate motion rates with, 178
 - aphasia with, 20
 - aspiration management and, 52–54
 - aspiration pneumonia with, 184
 - assessment of respiratory problems with, 14–15
 - assessment of swallowing function in, 43–44
 - assessment of, with ALS Severity Scale, 24–29, 42, 43–44, 55–57
 - association on, CD
 - benefits of early diagnosis, 6
 - cause of, 3–4
 - clinical stages of ambulatory function in, 9
 - cognitive changes with, x, 10–12
 - compared with other motor neuron diseases, 1–2
 - definition, 1, 221

- diagnosis, 5–6
 - eating habits and, 45–48
 - emotional and psychosocial aspects of, 8, 12, 30
 - employment for individuals with, 40
 - exercise for, 7–8
 - frontal lobe syndrome and, 11
 - frontotemporal dementia (FTD)/ALS and, 11–12
 - gender ratio in, 2
 - goals of rehabilitation for, 7
 - grief and depression with, 8
 - handout, CD
 - hospice admission criteria for, 10
 - incidence of, 2
 - management of respiratory problems with, 15–17
 - medications for, x, 6–7
 - muscle cramping and spasms in, 8
 - neurological changes with, x, 2–3
 - palliative care for, 9–10
 - patient autonomy and, 8–9
 - rate of speech changes in, 20, 22–24
 - rate of swallowing disorders in, 42–43
 - references on, 59–67
 - rehabilitation medicine for, 7–10
 - respiratory problems with, 12–17
 - saliva management and, 49–52
 - signs and symptoms of, ix, x, 1, 2, 3, CD
 - speech disorders with, x, 18–41, CD
 - speech intelligibility related to other variables in, 20, 21–22
 - speech treatment for, 29–41, CD
 - surgery for swallowing disorders with, 52, 53–54
 - survival data on, 2
 - swallowing disorders management for, 44–49
 - swallowing disorders with, x, 42–54, CD
 - typical course of, x, 4–5
 - weakness and, 3, 7, 8
- ANCDS. *See* Academy of Neurologic Communication Disorders and Sciences (ANCDS)
- Ankle-foot orthosis (AFO), 221
- Anticholinergic drugs, 79
- APDA. *See* American Parkinson Disease Association (APDA)
- Aphasia, 20
- Arizona Battery for Communication Disorders*, 149
- Artane, 79
- Articulation
 - definition, 221
 - with Parkinson's disease, 87, 88
- ASHA. *See* American Speech-Language-Hearing Association (ASHA)
- Aspiration, 221, CD
- Aspiration management, 52–54
- Aspiration pneumonia, 184
- Aspirator, 221
- Assessment. *See also* Diagnosis; Interviews; Speech and swallowing examination
 - of amyotrophic lateral sclerosis (ALS), 24–29, 42, 43–44, 55–57
 - of conversation and interaction, 198–200, 207–217
 - of dehydration, 51
 - Levels of Speech Usage Categorical Rating Scale, 158–159, 189–190
 - of lower and upper extremity function in ALS, 27–29, 57–58
 - of multiple sclerosis severity, 150–151
 - of Parkinsonian dysarthria, 95, 99

- of respiratory problems with ALS, 14–15, 43–44
 - of speech disorders (dysarthria) in ALS, 25–26, 55
 - of speech disorders (dysarthria) in Multiple sclerosis, 158–160
 - of speech function during clinical examination, 183, 187, 189–190
 - of swallowing function during clinical examination, 183, 187–188, 191
 - of swallowing function in ALS, 26–27, 42, 43–44, 56, 184
 - of swallowing function in Huntington’s disease, 135–137
 - of swallowing function in multiple sclerosis, 166
 - of swallowing function in Parkinson’s disease, 106–107
- Assistive technology. *See also* Augmentative communication system (AAC)
 - with Huntington’s disease, 138
 - with multiple sclerosis, 154
- Assistive ventilatory, 15–17
- Associations and organizations, CD
- Ataxia, 153, 157, 161–162, 221, CD
- Athetosis, 71
- Atrophy, 221, CD
- Audio recording of conversation, 199, 208–209, 215–217
- Auditory comprehension, 124
- Augmentative communication system (AAC)
 - alerting systems and, 37
 - alphabet boards and alphabet supplementation, 37, 102, 131–132, 163, 221
 - ALS Severity Scale and, 26
 - for amyotrophic lateral sclerosis (ALS), 36–41
 - classification of functional capabilities for, 38–39
 - for conversations, 196–197, 201–202, 206, 208
 - definition, 221, CD
 - employment of individuals with ALS using, 40
 - funding of, 40–41
 - handout, CD
 - for Huntington’s disease, 130
 - for multiple sclerosis, 163, CD
 - multipurpose systems for, 37–38
 - for Parkinson’s disease, 102, CD
 - patterns of system use, 39
 - portable writing systems and, 37
 - research center on, CD
 - speech-language pathologists (SLPs) and, 196–197
 - telephone communication and, 37
 - timing of AAC intervention, 36
- Autonomy of patients, 8–9
- Avonex, 152

- Basal ganglia, 70–71, 103, 122, 123, 221, CD
- Behavioral rate-control techniques, 100–101
- Betaseron, 152
- Bilevel Positive Air Pressure (BiPAP), 16
- BiPAP (Bilevel Positive Air Pressure), 16
- Bolus, 221
- Bradykinesia, 71–73, 221, CD
- Breathiness, 221
- Bromocriptine, 78
- Buccal/frontal/orbital muscles, 180–181
- Buccinators, 179–180, 187

- Cachexia, 221
- Calendars and memory aids, 132, 154
- Catechol-*O*-methyltransferase (COMT), 79



- Center for Neurologic Study—Lability Scale, 12
- Centers for Disease Control, 182
- Central nervous system (CNS), 147, 150, 221
- Charcot's disease. *See* Amyotrophic lateral sclerosis (ALS)
- Choking
 - first aid for, 46, CD
 - multiple sclerosis and, 166
- Chorea, 71, 122, 124, 221
- Clinical examination. *See* Speech and swallowing examination
- CNS. *See* Central nervous system (CNS)
- Cognitive problems
 - with amyotrophic lateral sclerosis (ALS), x, 10–11
 - frontal lobe syndrome and, 11
 - frontotemporal dementia (FTD)/ALS, 11–12
 - with Huntington's disease, x, 123–124, 128–130
 - with multiple sclerosis, x, 148–149, 154
 - with Parkinson's disease, x, 81–82, CD
- Cogwheel rigidity, 221
- Communication. *See* Conversation and interaction
- Communication Independence for the Neurologically Impaired, 38
- "Computerized Speech Lab," 162–163
- COMT. *See* Catechol-*O*-methyltransferase (COMT)
- Comtan, 79
- Contractures, 222
- Conversation and interaction
 - assessment of, 198–200, 207–217
 - augmentative communication system (AAC) for, 196–197, 201–202, 206, 208
 - case examples, 207–208
 - conversation starters for people with Huntington's disease, 132–133
 - direct observation/analysis of, 199–200, 208–209, 215–217
 - gaining attention for, 205
 - Huntington's disease and, 124
 - impact of dysarthria on, 196–197
 - importance and organization of, 195–196
 - interview for assessment of, 198–199, 207, 211–213
 - Levels of Speech Usage Categorical Rating Scale, 158–159, 189–190
 - management of, 203–209
 - opportunities for, 198
 - perception of current problems with, 198
 - preferences and styles in, 198
 - problems with, 198–199, CD
 - profiles of conversation partnership, 200–207
 - recording of, 199, 208–209, 215–217
 - references on, 219–220
 - role of speech–language pathologists in, 196–197
 - showing understanding for, 205, 206
 - strategies for, 199
 - tips for, CD
 - topic initiation and topic change for, 206
 - turn design for, 206
- Copaxone, 152
- Cough, 14, 17, 182
- Counseling. *See* Psychological services and counseling
- Cuirass, 222

- DAF. *See* Delayed auditory feedback (DAF)
- DBS. *See* Deep brain stimulation (DBS)

- Decomposition, CD
- Deep brain stimulation (DBS), 79–80, 91
- Degenerative diseases. *See specific diseases*
- Dehydration, 51. *See also* Liquid intake
- Delayed auditory feedback (DAF), 101, 222
- Dementia
 - definition, 222
 - frontotemporal dementia (FTD)/ALS, 11–12
 - with Parkinson's disease, 81, 82
- Deprenyl, 78–79
- Depression. *See also* Affective disorders
 - with amyotrophic lateral sclerosis (ALS), 8
 - with Huntington's disease, 123
 - major depressive disorder (MDD), 150
 - with multiple sclerosis, 150
 - with Parkinson's disease, 80–81, 82
- Diadochokinetic rates, 160, 177–179, 222
- Diagnosis. *See also* Assessment; Speech and swallowing examination
 - of amyotrophic lateral sclerosis (ALS), 5–6
 - of Huntington's disease, 124–125
 - of multiple sclerosis, 150
 - of Parkinson's disease, 73
- Dietary changes
 - for gastroesophageal reflux disease (GERD), CD
 - Huntington's disease and, 138
 - Parkinson's disease and, 109
 - for swallowing difficulties, 27, 47–48, CD
- Direct observation/analysis of conversation, 199–200, 208–209, 215–217
- Direct selection, 222
- Disease-modifying therapy, 152
- Dopamine, 222, CD
- Dopamine breakdown inhibition, 78–79
- Dopamine imitators, 78
- Dopamine replacement, 78
- Double swallow, 46
- Drug management. *See* Medications
- Durable power of attorney for health care, 222
- Dysarthria. *See* Speech disorders (dysarthria)
- Dyskinesia, 222
- Dysmetria, 153
- Dysphagia. *See* Swallowing disorders (dysphagia)
- Dysphagia Severity Rating Scale, 107, 108
- Dystonia, CD
- Dystonic syndrome, 70–71

- Eating. *See* Dietary changes; Feeding; Swallowing disorders (dysphagia); Tube feeding
- EDSS (*Expanded Disability Status Scale*), 151
- El Escorial criteria, 5
- Eldepryl, 78–79
- Emergency procedures for choking, 46, CD
- Emotional lability, 12, 222. *See also* Affective disorders; Depression
- Employment
 - compensatory techniques for individuals with multiple sclerosis in, 155
 - of individuals with ALS using AAC, 40
 - of individuals with multiple sclerosis, 154–155
- Entacapone, 79
- Epiglottic sew-down procedures, 17, 54

- Evaluation. *See* Assessment; Diagnosis; Speech and swallowing examination
- Exacerbations, CD
- Examination. *See* Speech and swallowing examination
- Exercise, 7–8. *See also* Rehabilitation
- Expanded Disability Status Scale* (EDSS), 151, 165
- Extrapyramidal system, 222
- Extremity function. *See* Lower extremity function; Upper extremity function
- Eye-gaze systems, 41

- Fasciculations, 222
- Fatigue, 149, 153–155, 167
- Feeding. *See also* Dietary changes; Swallowing disorders; Swallowing disorders management; Tube feeding
 - alternative feeding for people with Huntington’s disease, 138
 - calorie-dense foods, 47
 - control of eating rate and bite size, 138
 - definition, 222
 - early eating problems and ALS, 45, 46–47
 - multiple sclerosis and, 165
 - normal eating habits and ALS, 45
 - Parkinson’s disease and, 109
 - slowed eating, CD
- Festination, 222
- Fibrillations, 222
- First aid for choking, 46, CD
- Flaccid dysarthria, 223
- Flaccidity, 223, CD
- Food. *See* Dietary changes; Feeding; Swallowing disorders
- Forced vital capacity (FVC), 14–15, 44, 182
- Frontal lobe syndrome, 11
- Frontotemporal dementia (FTD)/ALS, 11–12
- FTD. *See* Frontotemporal dementia (FTD)/ALS
- Functional status, 150–151
- FVC. *See* Forced vital capacity (FVC)

- GABA (gamma-aminobutyric acid), 122
- Gag reflex, 223
- Gamma-aminobutyric acid (GABA), 122
- Gastroesophageal reflux disease (GERD), CD
- Gastrostomy, 223
- GERD. *See* Gastroesophageal reflux disease (GERD)
- Glatiramer, 152
- Grief. *See* Depression

- Harshness, 223
- HDSA. *See* Huntington’s Disease Society of America (HDSA)
- Heartburn, CD
- Heat sensitivity, 150
- Heimlich maneuver, CD
- Hemiballismus, 71
- Hoarseness, 223
- Hoehn and Yahr Functional Rating Scale for Parkinson’s disease, 75–76
- Hospice admission for ALS, 10
- Huntington’s disease
 - age at onset of, x
 - alphabet boards for people with, 131–132
 - alternative feeding for people with, 138
 - assistive devices for people with, 138
 - association on, CD

- augmentative communication system (AAC) for, 130
- calendars and memory aids for people with, 132
- characteristics of generally, ix
- clinical variants of, 122
- cognitive problems with, x, 123–124, 128–130
- conversation starters for people with, 132–133
- definition, 121, 223
- diagnosis, 124–125
- dietary changes for, 138
- emotional disturbances with, 123
- handout, CD
- hereditary nature of, 121, 125, 126
- incidence of, 121
- making choices for people with, 132
- management of mild dysarthria and cognitive changes with, 128–129
- management of moderate dysarthria and cognitive changes with, 129–130
- management of severe dysarthria with, 129, 130–134
- measurement of functional progression of, 125
- medical management of, 126
- medications for, x
- motor disturbances with, 122–123
- natural speech with supportive partners, 131
- neurological changes with, x, 121–122
- postural and positional changes for people with, 137–138
- references on, 141–143
- remotivation therapy for people with, 134
- respiratory chorea with, 124
- signs and symptoms of, x, 121, 122–124, CD
- speech characteristics associated with, 127–128
- speech disorders with, x, 124, 126, 127–134, CD
- speech treatment for, 128–134, CD
- supervision to control eating rate and bite size for people with, 138
- swallowing characteristics associated with, 135, 136
- swallowing disorders management for, 137–138
- swallowing disorders with, x, 135–138, CD
- yes/no system for people with, 133–134, 139
- Huntington’s Disease Society of America (HDSA), CD
- Hyperkinetic dysarthria, 86, 127, 223
- Hypernasality, 223
- Hypokinetic dysarthria, 86, 223
- Hypotonia, 223

- ICF. *See International Classification of Functioning, Disability and Health (ICF)*
- Idiopathic Parkinson’s disease, 69
- Immunomodulatory agents, 152
- Incidence, definition of, 223
- “Intention” tremor, 147, 153, 155
- Interaction. *See Conversation and interaction*
- Interferon beta-1a, 152
- Interferon beta-1b, 152
- International Classification of Functioning, Disability and Health (ICF)*, 130
- Interviews. *See also Assessment*
 - for assessment of conversation, 198–199, 207, 211–213
 - for assessment of Parkinsonian dysarthria, 95
 - for speech assessment in multiple sclerosis, 158–159
 - Swallowing Disorders Interview Worksheet, 191
 - for swallowing evaluation in Huntington’s disease, 136
 - for swallowing evaluation in Parkinson’s disease, 106

- Jobs. *See* Employment
- Juvenile Huntington's disease, 122

- KayPENTAX, 162
- Kennedy disease, 1, 2

- Language deficits. *See also* Speech disorders (dysarthria)
 - with Huntington's disease, 123–124
 - management of, with Huntington's disease, 128–133
 - with multiple sclerosis, 149
 - with Parkinson's disease, 82
- Laryngeal penetration, 223
- Laryngectomy, 17, 54
- Laryngotracheal separation, 17
- Lee Silverman Voice Treatment (LSVT), 80, 98–99
- Lenticular nucleus, 70
- Lentiform nucleus, 70
- Levels of Speech Usage Categorical Rating Scale, 158–159, 189–190
- Levodopa, 78, 79, 83, 103, 223
- Lips, examination of, 177–179, 186
- Liquid intake
 - assessment and treatment of dehydration, 51
 - maintenance of, 46, 47
 - swallowing disorders and, 46, 47–48, CD
 - taste, temperature, texture sensations of liquids, 47–48
 - washing foods down with liquids, 47
- Living will, 177, 223
- Lou Gehrig's disease. *See* Amyotrophic lateral sclerosis (ALS)
- Lower extremity function
 - assessment of, with ALS Severity Scale, 27–29, 57
 - definition, 223
- Lower motor neurons, 223, CD
- LSVT. *See* Lee Silverman Voice Treatment (LSVT)

- Magnetic resonance imaging (MRI), 5, 146–147, 150
- Major depressive disorder (MDD). *See* Depression
- MAO. *See* Monoamine oxidase (MAO)
- Mastication muscles, 179–180, 187
- Mayo Clinic, 69, 78
- MDA. *See* Muscular Dystrophy Association (MDA)
- MDD (major depressive disorder). *See* Depression
- Mechanical insufflation/exsufflation (MIE), 17
- Medical history, 158–159, 176, 185
- Medical management. *See also* Medications; Speech and swallowing examination; Surgery
 - of Huntington's disease, 126
 - of Parkinson's disease, 77–80, 81
- Medicare, 40–41
- Medications
 - for amyotrophic lateral sclerosis (ALS), x, 6–7
 - disease-modifying therapy with, 152
 - for Huntington's disease, x
 - for multiple sclerosis, x, 152
 - for Parkinson's disease, x, 77–79, 83, 90–91
 - for saliva management, 51–52
 - for speech disorders (dysarthria), 90–91
 - for swallowing disorders (dysphagia), 107, 109
- Memory aids and calendars, 132, 154
- Memory problems. *See* Cognitive problems

- MIE. *See* Mechanical insufflation/exsufflation (MIE)
- Mirapex, 78
- Mitoxantrone, 152
- MNDs. *See* Amyotrophic lateral sclerosis (ALS); Motor neuron diseases (MNDs)
- Monoamine oxidase (MAO), 78
- Monoamine oxidase-B, 78
- Motor disturbances
 - with Huntington's disease, 122–123
 - with multiple sclerosis, 147, 163–164
- Motor neuron diseases (MNDs), 1–2. *See also* Amyotrophic lateral sclerosis (ALS)
- Motor neurons, CD
- MRI (magnetic resonance imaging), 5, 146–147, 150
- MSA. *See* Multiple system atrophy (MSA)
- Multiple sclerosis
 - affective disorders with, 150
 - age at onset of, x, 146, 151
 - alphabet board supplementation for, 163
 - associations on, CD
 - ataxia and, 153, 157, 161–162, CD
 - characteristics of generally, ix
 - choking with, 166
 - cognitive changes with, x, 148–149, 154
 - definition, 145, 224
 - diagnosis, 150
 - early stages of, 166–167
 - employment and, 154–155
 - epidemiology of, 146
 - fatigue with, 149, 153–155, 167
 - functional status of, 150–151
 - handout, CD
 - heat sensitivity with, 150
 - late stages of, 167
 - magnetic resonance imaging (MRI) and, 146–147, 150
 - medications for, x, 152
 - mild dysarthria with, 161–162
 - moderate dysarthria with, 161, 162–163
 - motor symptoms of, 147, 163–164
 - neurological changes with, x, 145
 - paced speech for, 162–163
 - primary progressive MS, 151
 - prognosis of, 151–152
 - progression of changing function in, x, 150–152
 - progressive-relapsing MS, 151
 - references on, 169–173
 - rehabilitation for, 153–155
 - relapsing-remitting MS, 149, 151
 - respiratory pattern stabilization program for, 162
 - respiratory patterning for, 163
 - risk factors for, 146
 - secondary progressive MS, 151
 - sensory symptoms of, 148, 155
 - severe dysarthria with, 161, 163–164
 - signs and symptoms of, x, 147–150, 153, CD
 - sites of central nervous system (CNS) lesions and impairment in, 147, 150
 - spasticity with, 147, 153, 156–157, 162
 - speech assessment issues for, 158–160
 - speech characteristics associated with, 156
 - speech disorders with, x, 156–164, CD

- speech treatment for, 160–164, CD
 - swallowing difficulty management for, 166–167
 - swallowing disorders with, x, 165–167, CD
 - visual-motor problems with, 163–164
 - vocabulary selection for, 164
- Multiple system atrophy (MSA), 69, 73–74, 82, 86
- Muscle cramping and spasms, 8
- Muscular Dystrophy Association (MDA), CD

- Naming, 124
- Nasal emission, 224
- Nasogastric tube, 224
- Natalizumab, 152
- National Institute of Neurological Disorders and Stroke (NINDS), 7, CD
- National Multiple Sclerosis Society, 152, CD
- National Parkinson Foundation (NPF), CD
- NINDS. *See* National Institute of Neurological Disorders and Stroke (NINDS)
- NIV. *See* Noninvasive ventilation (NIV)
- Noninvasive ventilation (NIV), 15–17
- Normal eating habits, 45
- Normal speech production, 31–32, CD
- Normal swallowing, CD
- Nothing by mouth. *See* NPO (nothing by mouth)
- Novantrone, 152
- NPO (nothing by mouth)
 - ALS Severity Scale and, 27
 - definition, 224
 - dysphagia and, 49

- Observation/analysis of conversation, 199–200, 208–209, 215–217
- Occupational therapy, 81
- Oculogyric crisis, 224
- Olivopontocerebellar atrophy (OPCA), 74
- On-off effect, 224
- OPCA. *See* Olivopontocerebellar atrophy (OPCA)
- Organizations and associations, CD

- Paced speech, 162–163
- Pacing board, 102
- Palatal lift prosthesis, 35, 224
- Palate, 179–180, 187
- Palilalia, 102, 224
- Palliative care, 9–10
- Pallidotomy, 79, 91
- Paralysis agitans, 224
- Parkinson Alliance, CD
- Parkinson plus syndromes, 69, 73–75, 86
- Parkinson's disease
 - age at onset of, x
 - associations on, CD
 - behavioral intervention (speech treatment) for, 91–95
 - characteristics of generally, ix
 - cognitive problems with, x, 81–82, CD
 - compared with Parkinson plus syndromes, 69, 73–75, 86
 - compared with progressive supranuclear palsy (PSP), 69, 74–75, 86, 105–106, 224
 - definition, 69, 224
 - depression with, 80–81, 82

- diagnosis, 73
- feeding and dietary modifications for, 109
- handout, CD
- Hoehn and Yahr Functional Rating Scale for, 75–76
- idiopathic Parkinson’s disease, 69
- incidence of, 69
- language deficits with, 82
- medical management of, 77–80
- medications for, x, 77–79, 83
- natural course of, x
- neurological changes with, x, 70–71
- problems associated with, 80–83
- progression of dysarthria with, 88–90
- rate of progression of, 75–77
- references on, 111–119
- rehabilitation for, 80, 81
- respiratory problems with, 82–83, 86–87, 97
- secondary or acquired Parkinson’s disease, 69
- sensitivity of clinical signs of, 73
- signs and symptoms of, x, 71–73, CD
- specificity of clinical signs of, 73, 84–102
- speech characteristics associated with, 84–86
- speech disorders with, x, 84–102, CD
- speech scale for, 90
- speech treatment for, 90–102, CD
- surgery for, 79–80, 91
- swallowing disorders management for, 107–109
- swallowing disorders with, x, 103–109, CD
- Unified Parkinson’s Disease Rating Scale (UPDRS), 76, 77
- Parkinson’s Disease Foundation (PDF), 78, CD
- Parlodel, 78
- Patient autonomy. *See* Autonomy of patients
- Patient’s history, 175–177, 185
- PBP. *See* Progressive bulbar palsy (PBP)
- PDF. *See* Parkinson’s Disease Foundation (PDF)
- Peak expiratory cough flow (PECF), 14, 17
- PECF. *See* Peak expiratory cough flow (PECF)
- PEG. *See* Percutaneous endoscopic gastrostomy (PEG)
- Percutaneous endoscopic gastrostomy (PEG), 14, 44, 48, 109, 224
- Peripheral nervous system, 224
- Pharmacological intervention. *See* Medications
- Pharyngeal constrictors, 179–180, 187
- Phonation
 - with amyotrophic lateral sclerosis (ALS), 181
 - definition, 224
 - with Parkinson’s disease, 87, 96–99
 - sustained phonation measure, 160
- Phonatory instability, 224
- Physical examination. *See* Speech and swallowing examination
- Physical therapy, 81
- PLS. *See* Primary lateral sclerosis (PLS)
- PMA. *See* Primary progressive muscular (spinal) atrophy (PMA)
- Portable writing systems, 37
- Postural instability, 71–73
- Pramipexole, 78
- Prevalence, definition of, 224
- Primary lateral sclerosis (PLS), 2

- Primary progressive muscular (spinal) atrophy (PMA), 2
- Procedural memory, 224
- Progressive bulbar palsy (PBP), 2
- Progressive supranuclear palsy (PSP), 69, 74–75, 86, 105–106, 224
- PSP. *See* Progressive supranuclear palsy (PSP)
- Psychological services and counseling, 81. *See also* Affective disorders
- Pulmonary function tests, 15, 182, 224

- Randomly selected sentences, 160
- Rate-control techniques for Parkinsonian dysarthria, 100–101
- Rating scales
 - Dysphagia Severity Rating Scale, 107, 108
 - Levels of Speech Usage Categorical Rating Scale, 158–159, 189–190
 - for Parkinson's disease, 75–77, 99
 - for speech characteristics in Parkinson's disease, 99
 - Swallowing Performance Scale, 166
- Reading of a standard passage, 160
- Reading of randomly selected sentences, 160
- Rebif, 152
- Recording of conversation, 199, 208–209, 215–217
- Rehabilitation
 - for amyotrophic lateral sclerosis (ALS), 7–10
 - exercise and, 7–8
 - goals of, 7
 - for multiple sclerosis, 153–155
 - palliative care and, 9–10
 - for Parkinson's disease, 80, 81
 - patient autonomy and, 8–9
- Rehabilitation Engineering Research Center on AAC (AAC-RERC), CD
- Remissions, CD
- Remotivation therapy, 134
- Requip, 78
- Respiration, 224. *See also* Respiratory problems
- Respiratory pattern stabilization program, 162
- Respiratory patterning, 163
- Respiratory problems
 - with amyotrophic lateral sclerosis (ALS), 12–17, 43–44
 - assessment of, 14–15, 43–44
 - assistive ventilatory, 15–16
 - examination of respiratory muscles, 181–182, 187
 - management of, 15–17
 - with multiple sclerosis, 161–164
 - with Parkinson's disease, 82–83, 86–87, 97
 - respiratory chorea with Huntington's disease, 124
 - speech production and, 86–87, 97
 - swallowing disorders and, 43–44
- Respiratory pump muscles, 181–182
- Respiratory valve muscles, 182
- Respirometer, 182, 224
- Resting tremor, CD, 71–72, 224
- Rigid syndrome, 71
- Rigidity
 - definition, 225
 - with Huntington's disease, 122
 - with Parkinson's disease, 71–73, CD
- Riluzole, 6
- Ropinirole, 78

- Saliva management, 49–52, CD
- Scanning speech, 156
- Secondary or acquired Parkinson's disease, 69
- Selegiline, 78–79
- Sensitivity of clinical signs of Parkinson's disease, 73
- Sensory symptoms of multiple sclerosis, 148, 155
- Shy-Drager syndrome, 74, 86
- SLPs. *See* Speech–language pathologists (SLPs)
- SND. *See* Striatonigral degeneration (SND)
- Social interaction. *See* Conversation and interaction
- Spastic dysarthria, 86, 225
- Spasticity
 - with amyotrophic lateral sclerosis (ALS), CD
 - definition, 225, CD
 - with multiple sclerosis, 147, 153, 156–157, 162
- Specificity of clinical signs of Parkinson's disease, 73
- Speech and swallowing examination
 - of buccal/frontal/orbital muscles, sternocleidomastoid/trapezius muscles, and vocal folds, 180–181
 - current health care management, 176–177, 186
 - diadochokinetic rates, 160, 177–179, 222
 - form for, 185–188
 - for Huntington's disease, 136
 - Levels of Speech Usage Categorical Rating Scale, 158–159, 189–190
 - medical history, 176, 185
 - for multiple sclerosis, 160
 - of palate, muscles of mastication, pharyngeal constrictors, and buccinators, 179–180, 187
 - for Parkinson's disease, 95, 107
 - patient's history, 175–177, 185
 - physical examination, 177–182, 186–187
 - reading of a standard passage, 160
 - reading of randomly selected sentences, 160
 - references on, 193–194
 - of respiratory muscles, 181–182, 187
 - speech function assessment, 183, 187, 189–190
 - sustained phonation, 160
 - Swallowing Disorders Interview Worksheet, 191
 - swallowing function assessment, 183–184, 187–188, 191
 - of tongue and lips, 177–179, 186
- Speech disorders (dysarthria). *See also* Conversation and interaction; Language deficits; Speech and swallowing examination; Speech production; Speech treatment
 - with amyotrophic lateral sclerosis (ALS), x, 18–41, CD
 - articulation and, 87, 88
 - assessment of, in clinical examination, 183, 187, 189–190
 - assessment of Parkinsonian dysarthria, 95, 99
 - assessment of, with ALS Severity Scale, 25–26, 55
 - assessment of, with multiple sclerosis, 158–160
 - ataxia and, 153, 157, 161–162, CD
 - compensation strategies for, CD
 - definition of dysarthria, 222, CD
 - handout, CD
 - with Huntington's disease, x, 124, 126, 127–134, CD
 - impact of, on conversations, 196–197
 - medications for, 90–91
 - mild dysarthria and cognitive change with Huntington's disease, 128–129
 - mild dysarthria with multiple sclerosis, 161–162
 - mild Parkinsonian dysarthria, 96–99
 - moderate dysarthria and cognitive change with Huntington's disease, 129–130



- moderate dysarthria with multiple sclerosis, 161, 162–163
 - moderate Parkinsonian dysarthria, 96, 99–101
 - with multiple sclerosis, x, 156–164, CD
 - with Parkinson plus syndromes, 86
 - with Parkinson's disease, x, 84–102, CD
 - phonation and, 87, 96–99
 - rate of progression of, in Parkinson's disease, 88–90
 - rate of speech changes in ALS, 20, 22–24
 - respiration and, 86–87
 - scanning speech, 156
 - severe dysarthria with Huntington's disease, 129, 130–134
 - severe dysarthria with multiple sclerosis, 161, 163–164
 - severe Parkinsonian dysarthria, 96, 101–102
 - spasticity and, 156–157, 162
 - speech intelligibility related to other variables in ALS, 20, 21–22
 - speech rate and, 87, 88
 - stages of, 25–26
 - velopharyngeal function and, 87, 88
- Speech-generating devices, 102
- Speech intelligibility, 225
- Speech–language pathologists (SLPs), 196–197
- Speech production. *See also* Speech disorders (dysarthria)
 - articulation and, 87, 88
 - components of, in Parkinson's disease, 86–88
 - handout, CD
 - normal speech processes with amyotrophic lateral sclerosis (ALS), 31–32
 - normal speech production, CD
 - phonation and, 87, 96–99
 - respiration and, 86–87, 97
 - speech rate, 87, 88
 - structures for, CD
 - velopharyngeal function and, 87, 88
- Speech rate with Parkinson's disease, 87, 88
- Speech treatment. *See also* Augmentative communication system (AAC)
 - alphabet boards and alphabet board supplementation, 37, 102, 131–132, 163, 221
 - for amyotrophic lateral sclerosis (ALS), 29–41, CD
 - behavioral intervention for, 91–95
 - behavioral modifications and, 31, 34–36
 - behavioral rate-control techniques, 100–101
 - calendars and memory aids, 132, 154
 - communication for patients on ventilators, 41
 - conversation starters, 132–133
 - delayed auditory feedback (DAF), 101
 - for detectable speech disturbance, 31, 32–34
 - eye-gaze systems, 41
 - for Huntington's disease, 128–134, CD
 - Lee Silverman Voice Treatment (LSVT), 80, 98–99
 - loss of useful speech and, 41
 - making choices, 132
 - for mild dysarthria and cognitive change with Huntington's disease, 128–129
 - for mild dysarthria with multiple sclerosis, 161–162
 - for mild Parkinsonian dysarthria, 96–99
 - for moderate dysarthria and cognitive change with Huntington's disease, 129–130
 - for moderate dysarthria with multiple sclerosis, 161, 162–163
 - for moderate Parkinsonian dysarthria, 96, 99–101
 - for multiple sclerosis, 161–164, CD
 - natural speech with supportive partners, 131

- normal speech processes and, 31–32
 - paced speech, 162–163
 - pacing board, 102
 - for Parkinson’s disease, 81, 90–102, CD
 - principles for intervention, 29–30
 - respiratory pattern stabilization program, 162
 - respiratory patterning, 163
 - for severe dysarthria with Huntington’s disease, 129, 130–134
 - for severe dysarthria with multiple sclerosis, 161, 163–164
 - for severe Parkinsonian dysarthria, 96, 101–102
 - speech-generating devices, 102
 - staging of intervention, 30–41
 - “theater voice,” 100
 - visual-motor problems with multiple sclerosis, 163–164
 - vocabulary selection and, 164
 - voice amplifiers, 101
 - yes/no systems, 41, 133–134, 139
- Spinemet, 225
- Spinobulbar muscular atrophy (Kennedy disease), 1, 2
- Spirantization, 225
- Sternocleidomastoid/trapezius muscles, 180–181
- Steroids, 152
- Strained-strangled voice, 225
- Striatonigral degeneration (SND), 74
- Subchoreatic state of Huntington’s disease, 122
- Substantia nigra, CD
- Surgery. *See also* Tube feeding
 - for aspiration management, 53–54
 - for Parkinson’s disease, 79–80, 91
 - for saliva management, 52
 - for speech disorders with Parkinson’s disease, 91
 - for swallowing disorders with ALS, 52, 53–54
- Sustained phonation, 160
- Swallow apnea, 43
- Swallowing. *See also* Speech and swallowing examination; Swallowing disorders; Swallowing disorders management
 - correct and incorrect positions for, 46, CD
 - double swallow, 46
 - neck flexion position for, 46
 - normal swallowing, CD
 - stages of, 225, CD
- Swallowing disorders (dysphagia). *See also* Speech and swallowing examination; Swallowing disorders management
 - with amyotrophic lateral sclerosis (ALS), x, 42–54, CD
 - assessment of, in clinical examination, 183, 187–188, 189–190
 - assessment of, with ALS Severity Scale, 26–27, 42, 43–44, 56
 - assessment of, with Huntington’s disease, 135–137
 - assessment of, with Parkinson’s disease, 106–107
 - definition, 222
 - early eating problems and, 45, 46–47
 - esophageal stage difficulties, 136, 137, CD
 - handouts, CD
 - with Huntington’s disease, x, 135–138, CD
 - interview worksheet for assessment of, 191
 - with multiple sclerosis, x, 165–167, CD
 - oral preparatory and oral stage difficulties, 136, 137, CD
 - with Parkinson’s disease, x, 81, 103–109, CD

- pharyngeal stage difficulties, 136, 137, CD
- with progressive supranuclear palsy (PSP), 105–106
- rate of progression of, in ALS, 42–43
- respiratory problems and, 43–44
- Severity Rating Scale for, 107, 108
- slowed eating due to, CD
- stages of, 26–27
- swallow apnea, 43
- symptoms of, with Parkinson’s disease, 104–105
- warning signs of, 184, CD
- Swallowing disorders management
 - for amyotrophic lateral sclerosis (ALS), 44–49
 - aspiration management, 52–54
 - assistive devices for, 138
 - compensation strategies, 109, CD
 - dietary changes for, 27, 47–48, 109, 138, CD
 - double swallow, 46
 - for Huntington’s disease, 137–138
 - liquid intake, 46, 47–48
 - medications, 107–108
 - for multiple sclerosis, 166–167
 - normal eating habits, 45
 - NPO (nothing by mouth), 27, 49
 - for Parkinson’s disease, 107–109
 - postural and positional changes for, 137–138
 - saliva management, 49–52, CD
 - staging of intervention, 45–49
 - supervision to control eating rate and bite size for, 138
 - tube feeding, 46–47
- Tasmar, 79
- Telephone communication, 37
- Thalamotomy, 79, 91
- “Theater voice,” 100
- TIV. *See* Tracheostomy invasive ventilation (TIV)
- Tolcapone, 79
- Tongue, 177–179, 186
- Tracheal diversion, 54
- Tracheoesophageal anastomosis, 17
- Tracheostomy, 225
- Tracheostomy invasive ventilation (TIV), 16
- Treatment. *See* Medications; Speech treatment; Surgery
- Tremor
 - definition, 225
 - “intention” tremor in multiple sclerosis, 147, 153, 155
 - Parkinson’s disease and, 71–73
 - resting tremor, CD
- Trihexyphenidyl, 79
- Tube feeding
 - ALS Severity Scale and, 27
 - definition of nasogastric tube, 27, 224
 - intervention strategies, 48
 - management of, 49
 - PEG (percutaneous endoscopic gastrostomy) for, 14, 44, 48, 109, 224
 - symptoms indicating need for, 48
 - timing of, 48–49
- Tysabri, 152

- Unified Parkinson's Disease Rating Scale (UPDRS), 76, 77
- University of Nebraska AAC Center, 38
- UPDRS. *See* Unified Parkinson's Disease Rating Scale (UPDRS)
- Upper extremity function
 - assessment of, with ALS Severity Scale, 27–29, 58
 - definition, 225
- Upper motor neurons, 225, CD

- Velopharyngeal function, with Parkinson's disease, 87, 88
- Velopharyngeal mechanism, definition, 225
- Ventilators, 41, 225
- Ventilatory assistance, 15–17
- Video recording of conversation, 199, 208–209, 215–217
- Vital capacity, 182, 225
- Vocabulary selection, 164
- Vocal fold closure, 54
- Vocal folds, 180–181
- Voice amplifiers, 101

- Weakness
 - in amyotrophic lateral sclerosis (ALS), 3, 7, 8
 - definition of, 225
 - in multiple sclerosis, 147, 153, 155
- Web sites, CD
- Westphal's variant of Huntington's disease, 122
- WHO. *See* World Health Organization (WHO)
- Workplace. *See* Employment
- World Federation of Neurology Research Group on Neuromuscular Disease, 5
- World Health Organization (WHO), 130

- Yes/no systems, 41, 133–134, 139